PURPOSE OF REVIEW: To discuss the relevance of triglycerides to cardiovascular disease (CVD) risk. RECENT FINDINGS: Triglycerides are a commonly measured component of lipid profiles. Raised triglycerides are a component of the metabolic syndrome and are strongly associated with future risk of diabetes as well as cardiovascular disease. Triglyceride-rich particles form a component of cardiovascular risk above that delineated by low density lipoprotein (LDL) cholesterol. Elevated triglycerides are a marker of atherogenic small dense LDL, excess baseline and residual CVD risk even after statin therapy. Additional methods to lower triglycerides include niacin, fibrates and omega-3 fatty acids. Trials in monotherapy with both niacin and fibrates suggest some benefit in reducing CVD events based on evidence mostly derived from older studies. However, endpoint trials of adding either niacin or fenofibrate to statins have not shown any benefit, except possibly in patients with an increased atherogenic index (triglyceride : HDL-C ratio), or have been underpowered. Trials of omega-3 fatty acids have been performed at doses insufficient to affect lipid profiles in populations with inadequate control of LDL-C but did reduce CVD events. SUMMARY: Further trials of lipid-lowering agents beyond statins will be required in patients with LDL-C adequately controlled on statin therapy.
PURPOSE OF REVIEW: To discuss the relevance of triglycerides to cardiovascular disease (CVD) risk. RECENT FINDINGS:Triglycerides are a commonly measured component of lipid profiles. Raised triglycerides are a component of the metabolic syndrome and are strongly associated with future risk of diabetes as well as cardiovascular disease. Triglyceride-rich particles form a component of cardiovascular risk above that delineated by low density lipoprotein (LDL) cholesterol. Elevated triglycerides are a marker of atherogenic small dense LDL, excess baseline and residual CVD risk even after statin therapy. Additional methods to lower triglycerides include niacin, fibrates and omega-3 fatty acids. Trials in monotherapy with both niacin and fibrates suggest some benefit in reducing CVD events based on evidence mostly derived from older studies. However, endpoint trials of adding either niacin or fenofibrate to statins have not shown any benefit, except possibly in patients with an increased atherogenic index (triglyceride : HDL-C ratio), or have been underpowered. Trials of omega-3 fatty acids have been performed at doses insufficient to affect lipid profiles in populations with inadequate control of LDL-C but did reduce CVD events. SUMMARY: Further trials of lipid-lowering agents beyond statins will be required in patients with LDL-C adequately controlled on statin therapy.
Authors: Vineeta Sharma; Andrzej Witkowski; H Ewa Witkowska; Andrew Dykstra; Jens B Simonsen; Lisa Nelbach; Jennifer A Beckstead; Clive R Pullinger; John P Kane; Mary J Malloy; Gordon Watson; Trudy M Forte; Robert O Ryan Journal: Arterioscler Thromb Vasc Biol Date: 2014-08-14 Impact factor: 8.311
Authors: Shu Wang; Nirupa R Matthan; Dayong Wu; Debra B Reed; Priyanka Bapat; Xiangling Yin; Paula Grammas; Chwan-Li Shen; Alice H Lichtenstein Journal: Clin Nutr Date: 2013-04-24 Impact factor: 7.324
Authors: Veronique Verhoeven; Anastasia Van der Auwera; Luc Van Gaal; Roy Remmen; Sandra Apers; Michel Stalpaert; Johan Wens; Nina Hermans Journal: BMC Complement Altern Med Date: 2015-03-10 Impact factor: 3.659
Authors: Todd C Rideout; Vanu Ramprasath; John D Griffin; Richard W Browne; Scott V Harding; Peter J H Jones Journal: Lipids Health Dis Date: 2014-01-06 Impact factor: 3.876
Authors: Vana Kolovou; Olga Diakoumakou; Athanasia K Papazafiropoulou; Niki Katsiki; Elisabeth Fragopoulou; Ioannis Vasiliadis; Dimitris Degiannis; Leonidas Duntas; Smaragdi Antonopoulou; Genovefa Kolovou Journal: Open Cardiovasc Med J Date: 2018-07-31
Authors: Sami T Azar; Hadi Abu Hantash; Selim Jambart; Mohamed M El-Zaheri; Rachoin Rachoin; Amal Chalfoun; Layla Lahoud; Osama Okkeh; Peter Bramlage; Philippe Brudi; Baishali M Ambegaonkar Journal: Vasc Health Risk Manag Date: 2014-05-07